A Bayesian K‐PD model for synergy: A case study

Coadministration of 2 or more compounds can alter both the pharmacokinetics and pharmacodynamics of individual compounds. While experiments on pharmacodynamic drug-drug interactions are usually performed in an in vitro setting, this experiment focuses on an in vivo setting. The change over time of a safety biomarker is modeled using an indirect response model, in which the virtual pharmacokinetic profile of one compound drives the effect of the other. Several experiments at different dose level combinations were performed sequentially. While a traditional frequentist analysis consists of estimating the model parameters based on all the data simultaneously, in this work, we consider a Bayesian inference framework allowing to incorporate the results from a historical dose-response experiment.

[1]  P S Hewlett,et al.  Measurement of the potencies of drug mixtures. , 1969, Biometrics.

[2]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.

[3]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[4]  G. Levy,et al.  RELATIONSHIP BETWEEN ELIMINATION RATE OF DRUGS AND RATE OF DECLINE OF THEIR PHARMACOLOGIC EFFECTS. , 1964, Journal of pharmaceutical sciences.

[5]  J. Wagner,et al.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.

[6]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[7]  Chris Harbron A flexible unified approach to the analysis of pre-clinical combination studies. , 2010, Statistics in medicine.

[8]  W. Jusko,et al.  Characterization of four basic models of indirect pharmacodynamic responses , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  W J Jusko,et al.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.

[10]  Gavin J. Gibson,et al.  Likelihood estimation for stochastic compartmental models using Markov chain methods , 2001, Stat. Comput..

[11]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[12]  R. Gieschke,et al.  Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  Jiqiang Guo,et al.  Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.

[14]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[15]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[16]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .